IDNA:NYE-iShares Genomics Immunology and Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 23.01

Change

+0.10 (+0.44)%

Market Cap

USD 0.12B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-18 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.88 (+1.30%)

USD 37.71B
FHLC Fidelity® MSCI Health Care In..

+0.91 (+1.33%)

USD 2.77B
FXH First Trust Health Care AlphaD..

+1.38 (+1.28%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

+0.49 (+0.53%)

USD 0.20B
SBIO ALPS Medical Breakthroughs ETF

+0.14 (+0.43%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+1.53 (+1.51%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.32 (+1.06%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.39 (+0.61%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.12 (+0.54%)

USD 6.89M
IHF iShares U.S. Healthcare Provid..

+0.90 (+1.74%)

N/A

ETFs Containing IDNA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.68% 19% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.68% 19% F 42% F
Trailing 12 Months  
Capital Gain -1.29% 19% F 27% F
Dividend Return 0.48% 44% F 5% F
Total Return -0.81% 24% F 21% F
Trailing 5 Years  
Capital Gain -22.63% 14% F 24% F
Dividend Return 3.08% 53% F 8% B-
Total Return -19.55% 14% F 16% F
Average Annual (5 Year Horizon)  
Capital Gain -6.62% 5% F 9% A-
Dividend Return -6.07% 5% F 8% B-
Total Return 0.55% 53% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 30.13% 14% F 35% F
Risk Adjusted Return -20.16% 5% F 11% F
Market Capitalization 0.12B 60% D- 29% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.